Theralase TechnologiesTLTFF +1.22%46 PS Ratio is 55.50 as of Jun. 29, 2026, which is 35% above its 10-year median of 40.96. GuruFocus rates TLTFF with a GF Score™ of 46/100 and a GF Value™ of $0.13 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Theralase Technologies ranks worse than 95.65% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Theralase Technologies's share price is $0.1665.
Theralase Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Hence, Theralase Technologies's PS Ratio for today is 55.50.
The historical rank and industry rank for Theralase Technologies's PS Ratio or its related term are showing as below:
TLTFF'
s PS Ratio Range Over the Past 10 Years
Min: 10.53 Med: 40.96 Max: 117.5
Current: 58.75
During the past 13 years, Theralase Technologies's highest PS Ratio was 117.50. The lowest was 10.53. And the median was 40.96.
TLTFF's PS Ratio is ranked worse than 95.65% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.87
vs TLTFF: 58.75
Theralase Technologies Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Theralase Technologies was 33.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -15.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -7.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -18.10% per year.
During the past 13 years, Theralase Technologies's highest 3-Year average Revenue per Share Growth Rate was 250.30% per year. The lowest was -35.90% per year. And the median was -10.50% per year.
Back to Basics: PS Ratio
Theralase Technologies (OTCPK:TLTFF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Theralase Technologies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's PS Ratio distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Theralase Technologies's Share Price of today is $0.1665. Theralase Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Theralase Technologies (TLTFF) has a PS Ratio of 55.50 as of Jun. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Theralase Technologies and its competitors. This is 35% above median its historical median of 40.96. Over the past decade, Theralase Technologies' PS Ratio has ranged from 10.53 to 117.50. According to the industry distribution chart, Theralase Technologies ranks #770 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 95.7%.
Is Theralase Technologies' PS Ratio too high?
Theralase Technologies' current PS Ratio of 55.50 is 35% above median its 10-year median of 40.96. Over the past 10 years, this metric has ranged from a low of 10.53 to a high of 117.50. The Medical Devices & Instruments industry median PS Ratio is 2.87. Theralase Technologies' value of 55.50 is 1833.8% above this industry median. Based on the distribution chart, Theralase Technologies ranks #770 out of 805 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Theralase Technologies has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theralase Technologies ranks #770 out of 805 companies for PS Ratio. This places Theralase Technologies in the lower half of its industry. The industry median PS Ratio is 2.87. Theralase Technologies' value of 55.50 is 1833.8% above this benchmark. Historically, Theralase Technologies' own PS Ratio has ranged from 10.53 to 117.50 over the past decade. While the company's 10-year median is 40.96 vs. the industry median of 2.87, Theralase Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.87, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theralase Technologies's current PS Ratio of 55.50 is 1833.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Theralase Technologies and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theralase Technologies's current PS Ratio is 55.50, which is 35% above median its own 10-year median of 40.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.17 — trading 28.1% above its estimated fair value. The current PS Ratio is 55.50, which is 35% above median its 10-year median of 40.96 and 1833.8% above the Medical Devices & Instruments industry median of 2.87. Theralase Technologies' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current PS Ratio is 55.50 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TLTFF) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of $0.17 is trading 28.1% above its estimated GF Value™ of $0.13.
GuruFocus considers Theralase Technologies to be Modestly Overvalued.
Key valuation signals for TLTFF:
PS Ratio: 55.50 (35% above median its 10-year median of 40.96)
GF Value™: $0.13 vs. price of $0.17 (28.1% above fair value)
Industry Position: 1833.8% above the Medical Devices & Instruments median (#770 of 805)
No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
46GF Score
Get the complete analysis for TLTFF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLTFF has been successfully added to your 
